Home › Migraine › Maryland › Baltimore
Migraine clinical trials in Baltimore, MD
4 studies for Migraine are looking for participants at sites in and around Baltimore (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
RecruitingPhase 3
- Pharmasite Research, Inc. /ID# 227908, Baltimore
Bilateral Embolization of the Middle Meningeal Arteries for Refractory Chronic Migraine
Recruiting
- Johns Hopkins Medicine, Baltimore
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
RecruitingPhase 3
- Headlands Research - PharmaSite, Pikesville · 8 mi away
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
RecruitingPhase 3
- University of Maryland School of Medicine, Baltimore
About Migraine
Migraines are pulsing or throbbing headaches in one area of the head. Learn about other symptoms, what triggers migraines, and how to treat them.
More about Migraine on MedlinePlus
Migraine trials in other cities
- Cincinnati, OH11 studies
- Austin, TX8 studies
- Miami, FL8 studies
- Philadelphia, PA8 studies
- Concord, CA8 studies
- Amherst, NY7 studies
- Omaha, NE7 studies
- Houston, TX7 studies
- Washington, DC7 studies
- Aurora, CO6 studies
- Stamford, CT6 studies
- San Diego, CA6 studies
Other studies in Baltimore
- Non-Small Cell Lung Cancer60 studies
- Breast Cancer47 studies
- Prostate Cancer43 studies
- Lung Cancer40 studies
- Cancer (all types)37 studies
- Colorectal Cancer31 studies
- Pancreatic Cancer31 studies
- Metastatic Cancer28 studies
- Obesity25 studies
- Heart Failure24 studies
- Bladder Cancer24 studies
- Stroke22 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.